High BIM mRNA levels are associated with longer survival in advanced gastric cancer
Por:
Wu, N, Huang, Y, Zou, Z, Gimenez-Capitan, A, Yu, LX, Hu, WJ, Zhu, LJ, Sun, X, Sanchez, JJ, Guan, WX, Liu, BR, Rosell, R and Wei, J
Publicada:
1 mar 2017
Resumen:
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS). All 131 patients received first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, in which 56 patients were further treated with second-line docetaxel-based chemotherapy. A correlation between the mRNA expression levels of BIM and AEG-1 was observed (r(s)=0.30; P=0.002). There was no association between the mRNA expression levels of any of the individual genes analyzed and OS in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM exhibited a median OS of 18.2 months [95% confidence interval (CI), 12.8-23.6], compared with 9.6 months (95% CI, 8.9-10.3) in patients with low BIM levels (P=0.008). However, there was no correlation between the mRNA expression levels of AEG-1 or AXL and OS. The risk of mortality was higher in patients with low BIM mRNA levels than in those with high or intermediate BIM mRNA levels (hazard ratio, 2.61; 95% CI, 1.21-5.62; P=0.010). Therefore, BIM may be considered as a biomarker to identify whether patients could benefit from docetaxel-based second-line chemotherapy in GC.
Filiaciones:
Wu, N:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Huang, Y:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Zou, Z:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Gimenez-Capitan, A:
USP Dexeus Univ Inst, Dept Oncol, Pangaea Biotech, Barcelona 08001, Spain
Yu, LX:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Hu, WJ:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Zhu, LJ:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Sun, X:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
Sanchez, JJ:
Autonomous Univ Madrid, Dept Prevent Med & Publ Hlth, Madrid 28001, Spain
Guan, WX:
Nanjing Univ, Sch Med, Dept Gen Surg, Affiliated Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China
Liu, BR:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Dept Med Oncol, Barcelona 08916, Spain
Wei, J:
Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp,Clin Canc Inst, Comprehens Canc Ctr Drum Tower Hosp,Dept Oncol,, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
gold, Green Published
|